History of organic brain disease
DSM-IV diagnosis of Alcohol or Substance Dependence within the last six months (except nicotine) or DSM-5 diagnosis of Substance Use Disorder in the last six months (except nicotine)
DSM-IV diagnosis of Alcohol or Substance Abuse within the last one month (except nicotine) or DSM-5 diagnosis of Substance Use Disorder in the last six months (except nicotine)
Pregnancy or lactation
Severe liver dysfunction (LFT 3X upper limit of normal)
Previous known hypersensitivity to tetracyclines
Current treatment with tetracycline or derivative
Treatment with oral contraceptives (unless a second form of birth control is used and documented)
Treatment with cholestyramine or colestipol
Treatment with Urinary alkalinizers (e.g., sodium lactate, potassium citrate)
Treatment with warfarin
Treatment with bupropion, varenicline, or nicotine replacement products in the month prior to study inclusion
Less than two months treatment of adjunctive medications AND less than one month on same dose: beta blockers, antidepressants, mood stabilizers, antianxiety medications.
Medical condition whose pathology or treatment would significantly increase the risk associated with the proposed protocol.
History of head injury, seizures, or stroke
Positive urine toxicology screen for substances of non-therapeutic use prior to craving assessments

NCT02968602_exc_T1
Condition
organic brain disease
NCT02968602_exc_T2
Observation
History of
NCT02968602_exc_T3
Qualifier
DSM-IV
NCT02968602_exc_T4
Condition
lcohol ependence
NCT02968602_exc_T5
Condition
Substance Dependence
NCT02968602_exc_T6
Scope
Alcohol or Substance Dependence
NCT02968602_exc_T7
Temporal
within the last six months
NCT02968602_exc_T8
Drug
nicotine
NCT02968602_exc_T9
Negation
except
NCT02968602_exc_T10
Qualifier
DSM-5
NCT02968602_exc_T11
Condition
Substance Use Disorder
NCT02968602_exc_T12
Temporal
in the last six months
NCT02968602_exc_T13
Drug
nicotine
NCT02968602_exc_T14
Negation
except
NCT02968602_exc_T15
Qualifier
DSM-IV
NCT02968602_exc_T16
Condition
cohol o use w
NCT02968602_exc_T17
Condition
Substance Abuse
NCT02968602_exc_T18
Scope
Alcohol or Substance Abuse
NCT02968602_exc_T19
Temporal
within the last one month
NCT02968602_exc_T20
Drug
nicotine
NCT02968602_exc_T21
Negation
except
NCT02968602_exc_T22
Qualifier
DSM-5
NCT02968602_exc_T23
Condition
Substance Use Disorder
NCT02968602_exc_T24
Temporal
in the last six months
NCT02968602_exc_T25
Drug
nicotine
NCT02968602_exc_T26
Negation
except
NCT02968602_exc_T27
Scope
DSM-5 diagnosis of Substance Use Disorder in the last six months (except nicotine)
NCT02968602_exc_T28
Condition
Pregnancy
NCT02968602_exc_T29
Condition
lactation
NCT02968602_exc_T30
Condition
liver dysfunction
NCT02968602_exc_T31
Qualifier
Severe
NCT02968602_exc_T32
Measurement
LFT
NCT02968602_exc_T33
Value
3X upper limit of normal
NCT02968602_exc_T34
Scope
LFT 3X upper limit of normal
NCT02968602_exc_T35
Condition
hypersensitivity
NCT02968602_exc_T36
Drug
tetracyclines
NCT02968602_exc_T37
Temporal
Previous
NCT02968602_exc_T38
Temporal
Current
NCT02968602_exc_T39
Procedure
treatment
NCT02968602_exc_T40
Drug
tetracycline
NCT02968602_exc_T41
Drug
ycline or de tive
Treat
NCT02968602_exc_T42
Scope
tetracycline or derivative
NCT02968602_exc_T43
Drug
oral contraceptives
NCT02968602_exc_T44
Procedure
Treatment
NCT02968602_exc_T45
Observation
birth control
NCT02968602_exc_T46
Qualifier
second form
NCT02968602_exc_T47
Negation
unless
NCT02968602_exc_T48
Drug
cholestyramine
NCT02968602_exc_T49
Drug
colestipol
NCT02968602_exc_T50
Procedure
Treatment
NCT02968602_exc_T51
Scope
cholestyramine or colestipol
NCT02968602_exc_T52
Procedure
Treatment
NCT02968602_exc_T53
Drug
Urinary alkalinizers
NCT02968602_exc_T54
Drug
sodium lactate
NCT02968602_exc_T55
Drug
potassium citrate
NCT02968602_exc_T56
Scope
sodium lactate, potassium citrate
NCT02968602_exc_T57
Drug
warfarin
NCT02968602_exc_T58
Procedure
Treatment
NCT02968602_exc_T59
Drug
bupropion
NCT02968602_exc_T60
Drug
varenicline
NCT02968602_exc_T61
Drug
nicotine replacement products
NCT02968602_exc_T62
Scope
bupropion, varenicline, or nicotine replacement products
NCT02968602_exc_T63
Temporal
in the month prior to study inclusion
NCT02968602_exc_T64
Reference_point
study inclusion
NCT02968602_exc_T65
Procedure
Treatment
NCT02968602_exc_T66
Multiplier
Less than two months
NCT02968602_exc_T67
Procedure
treatment
NCT02968602_exc_T68
Drug
adjunctive medications
NCT02968602_exc_T69
Multiplier
less than one month
NCT02968602_exc_T70
Multiplier
same dose
NCT02968602_exc_T71
Drug
beta blockers
NCT02968602_exc_T72
Drug
antidepressants
NCT02968602_exc_T73
Drug
mood stabilizers
NCT02968602_exc_T74
Drug
antianxiety medications
NCT02968602_exc_T75
Scope
beta blockers, antidepressants, mood stabilizers, antianxiety medications
NCT02968602_exc_T76
Condition
Medical condition
NCT02968602_exc_T77
Qualifier
would significantly increase the risk associated with the proposed protocol
NCT02968602_exc_T78
Condition
head injury
NCT02968602_exc_T79
Condition
seizures
NCT02968602_exc_T80
Condition
stroke
NCT02968602_exc_T81
Observation
History
NCT02968602_exc_T82
Scope
head injury, seizures, or stroke
NCT02968602_exc_T83
Measurement
urine toxicology screen
NCT02968602_exc_T84
Qualifier
substances of non-therapeutic use
NCT02968602_exc_T85
Value
Positive
NCT02968602_exc_T86
Temporal
prior to craving assessments
NCT02968602_exc_T87
Reference_point
craving assessments